



Corporate Profile / Main Group Companies

Corporate Profile

(As of April 1, 2019)

Company name DAIICHI SANKYO CO., LTD.
Established September 28, 2005
Business Research and development, manufacturing, import, sales, and marketing of pharmaceutical products
Share capital ¥50,000 million
Headquarters 3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo 103-8426, Japan
Branches Sapporo, Tohoku, Tokyo, Chiba, Saitama, Yokohama, Kanetsu, Tokai, Kyoto, Osaka, Kobe, Chugoku, Shikoku, and Kyushu

 Sales
  Manufacturing
  Research and development

U.S.A.

Daiichi Sankyo, Inc.  
 American Regent, Inc.  
 Plexxikon Inc.  

	FY2017 Results	FY2018 Results	YoY
Daiichi Sankyo, Inc.	74.8	36.3	-38.5
<i>Olmesartan</i>	21.3	10.7	-10.6
<i>Welchol</i>	33.9	13.4	-20.5
<i>Effient</i>	10.7	2.4	-8.2
<i>SAVAYSA</i>	2.2	2.3	+0.1
<i>MOVANTIK</i>	4.7	4.2	-0.5
American Regent, Inc.	105.4	117.8	+12.4
<i>Venofor</i>	31.0	28.9	-2.0
<i>Injectafer</i>	34.3	44.2	+9.9

Europe

- Daiichi Sankyo Europe GmbH
- Daiichi Sankyo Deutschland GmbH
- Daiichi Sankyo France SAS
- Daiichi Sankyo Italia S.p.A.
- Daiichi Sankyo España, S.A.
- Daiichi Sankyo UK Ltd.
- Daiichi Sankyo (Schweiz) AG
- Daiichi Sankyo Portugal, Unipessoal Lda.
- Daiichi Sankyo Austria GmbH
- Daiichi Sankyo Belgium N.V.-S.A.
- Daiichi Sankyo Nederland B.V.
- Daiichi Sankyo Ilac Ticaret Ltd. Şti.
- Daiichi Sankyo Ireland Ltd.
- Daiichi Sankyo Altkirch Sarl

	FY2017 Results	FY2018 Results	YoY
Daiichi Sankyo Europe	79.4	88.6	+9.1
<i>Olmesartan</i>	33.5	27.4	-6.1
<i>Effient</i>	8.0	5.7	-2.3
<i>LXIANA</i>	27.0	45.8	+18.8

Japan

- Daiichi Sankyo Espha Co., Ltd.
- Daiichi Sankyo Healthcare Co., Ltd.
- Daiichi Sankyo Propharma Co., Ltd.
- Daiichi Sankyo Chemical Pharma Co., Ltd.
- Daiichi Sankyo Biotech Co., Ltd.
- Daiichi Sankyo RD Novare Co., Ltd.
- Daiichi Sankyo Business Associe Co., Ltd.
- Daiichi Sankyo Happiness Co., Ltd.

	FY2017 Results	FY2018 Results	YoY
Domestic Prescription Drug and Vaccine Business	540.0	523.3	-16.7
<i>NEXIUM</i>	86.5	78.3	-8.3
<i>LXIANA</i>	45.3	64.9	+19.6
<i>Memary</i>	48.6	50.2	+1.7
<i>Loxonin</i>	36.5	30.5	-6.0
<i>PRALIA</i>	23.2	27.4	+4.2
<i>TENELIA</i>	26.3	25.3	-1.0
<i>Inavir</i>	25.3	18.2	-7.1
<i>Olmotec</i>	44.6	14.9	-29.7
<i>RANMARK</i>	15.4	16.4	+1.0
<i>Effient</i>	12.8	13.9	+1.1
<i>Rezaltas</i>	16.8	15.5	-1.3
<i>Urief</i>	11.1	10.3	-0.9
<i>Omnipaque</i>	14.0	12.0	-2.0
<i>CANALIA</i>	2.7	9.2	+6.5
<i>VIMPAT</i>	2.6	6.6	+3.9
Daiichi Sankyo Healthcare (OTC Related)	72.9	66.4	-6.5

ASCA*

- Daiichi Sankyo (China) Holdings Co., Ltd.
- Daiichi Sankyo Taiwan Ltd.
- Daiichi Sankyo Korea Co., Ltd.
- Daiichi Sankyo (Thailand) Ltd.
- Daiichi Sankyo Hong Kong Ltd.
- Daiichi Sankyo Brasil Farmaceutica LTDA.

* Asia, South & Central America

	FY2017 Results	FY2018 Results	YoY
Asia, South & Central America (ASCA)	80.4	87.7	+7.3
Daiichi Sankyo China	35.3	38.5	+3.2
Daiichi Sankyo Taiwan	6.6	7.1	+0.5
Daiichi Sankyo Korea	11.8	15.7	+3.9
Daiichi Sankyo Thailand	2.9	3.3	+0.3
Daiichi Sankyo Brasil	10.1	10.0	-0.1